The Hemophilia Learning Center

The Hemophilia Learning Center

This Learning Center is a freely accessible educational platform for healthcare providers who may be involved in the identification and management of patients with Hemophilia A and B. Our goal is to ensure that you – the practicing clinician – have access to the most accurate, up-to-date information for the treatment of patients with hemophilia.

We encourage you to share this educational resource with your colleagues and your healthcare team.

Guy Young, MD
Course Director

Mechanisms in Hemophilia Video Series

Be sure to check out the other videos in this series in the Resources section of the website.

Courses

Tipping the Scale Back Towards Normal: Evaluating Rebalancing Therapies to Achieve Hemostasis in Hemophilia

Credit Available: 1 AMA PRA Category 1 Credit(s)™

This activity will explore emerging rebalancing therapies for hemophilia A and B, focusing on their unique mechanisms of action and improved modes of administration to address limitations of traditional factor replacement therapy. Presentations will feature the latest clinical efficacy and safety data on these agents, along with discussions on their clinical implications for future hemophilia management.

Course Faculty: Guy Young, MD, Flora Peyvandi, MD, PhD, and Allison P. Wheeler, MD, MSCI 

Improving Quality of Life for People Living With Hemophilia: Strategies to Stratify Joint Damage Risk and Allow Increased Participation in Physical Activity

Credit Available: 1 AMA PRA Category 1 Credit(s)™

This activity will explore strategies aimed at improving quality of life for individuals with hemophilia, with specifics on reducing the risk of joint damage and promoting increased participation in physical activities. Topics will include practical assessments of joint health and methods for predicting progression of joint damage. Discussions also will highlight recent advancements in hemophilia management, with a focus on emerging rebalancing therapies that target coagulation pathways and their potential to minimize joint damage.

Course Faculty: Guy Young, MD, Roberta Gualtierotti, MD, PhD, and Allison P. Wheeler, MD, MSCI 

Achieving Freedom From Bleeding: Exploring the Evolving Evidence on New and Emerging Treatment Strategies to Maintain Higher FVIII Levels

Credit Available: 1 AMA PRA Category 1 Credit(s)™

This activity will explore innovative therapeutic approaches for hemophilia A, aiming to achieve and sustain higher factor VIII (FVIII) levels beyond conventional factor and non-factor therapies. Recent advancements, including high-sustained FVIII replacement and gene therapy, offer promise in maintaining near-normal FVIII levels with reduced dosing requirements, potentially improving joint bleed prevention and reducing treatment burden. Discussions will cover the clinical rationale for achieving higher FVIII levels, mechanisms of action of newer therapies, and the latest evidence on their efficacy and safety.

Course Faculty: Guy Young, MD, Michiel Coppens, MD, PhD, and Angela C. Weyand, MD 

Achieving and Sustaining Higher FVIII Levels in Hemophilia A: Exploring Real-world Strategies for Treatment and Monitoring Trough Levels Considering New Treatment Options

Credit Available: 1 AMA PRA Category 1 Credit(s)™

This expert panel discussion will explore practical strategies for achieving and sustaining higher factor VIII (FVIII) levels in patients with hemophilia A, with a focus on novel therapies such as high-sustained FVIII replacement therapy and gene therapy. Through case-based discussions featuring real-world patients, learners will be provided with strategies for setting personalized treatment goals, selecting tailored prophylactic regimens, and monitoring treatment efficacy and safety.

Course Faculty: Guy Young, MD, Michiel Coppens, MD, PhD, and Angela C. Weyand, MD

Reimagining Outcomes in Hemophilia: Improving Efficacy and Reducing Treatment Burden With High-Sustained Factor and NonFactor Replacement Therapies

Credit Available: 1.5 AMA PRA Category 1 Credit(s)™

This activity will discuss the unique mechanisms of actions of novel emerging agents that seek to provide less frequent dosing, the ability to address both hemophilia A and B, functionality in the presence of inhibitors, and more convenient routes of administration. The most recent clinical efficacy and safety data of these novel agents will be presented and their potential clinical integration using a patient-centric approach will be explored.

Course Faculty: Guy Young, MD, Glaivy Batsuli, MD and Cindy Leissinger, MD

Courses (expired)

Hemostasis in Hemophilia: How Improved Disease Knowledge Informs New Treatments

Credit Available (Expired): 0.75 AMA PRA Category 1 Credit(s)™

This activity will discuss the foundations of hemostasis and the pathology of hemophilia A and B. Using this foundation, Dr. Young will review novel treatment options, their mechanisms of action, and clinical data.

[Accreditation has expired. For informational purposes only.]

Course Faculty: Guy Young, MD

Optimizing Management in Hemophilia B: Exploring the Impact of Extravascular Distribution of Hemostasis

Credit Available (Expired): 0.75 AMA PRA Category 1 Credit(s)™

This activity will discuss unique considerations in the management of hemophilia B related to extravascular distribution of Factor IX (FIX). Dr. Sidonio will explore the molecular intricacies of FIX distribution and how that impacts pharmacokinetics and therapeutic monitoring of hemophilia B treatment effectiveness.

[Accreditation has expired. For informational purposes only.]

Course Faculty: Robert F. Sidonio, Jr, MD, MSc